Health & Fitness
Tue, January 29, 2013Mon, January 28, 2013Sun, January 27, 2013Sat, January 26, 2013Fri, January 25, 2013Thu, January 24, 2013Wed, January 23, 2013Tue, January 22, 2013Mon, January 21, 2013Fri, January 18, 2013Thu, January 17, 2013Wed, January 16, 2013Tue, January 15, 2013Mon, January 14, 2013Fri, January 11, 2013Thu, January 10, 2013Wed, January 9, 2013Tue, January 8, 2013Mon, January 7, 2013Sun, January 6, 2013Fri, January 4, 2013Thu, January 3, 2013Wed, January 2, 2013Mon, December 31, 2012Fri, December 28, 2012Uroplasty To Issue Third Quarter Of Fiscal 2013 Financial Results On January 24, 2013
//health-fitness.news-articles.net/content/2013/ .. l-2013-financial-results-on-january-24-2013.html
Published in Health and Fitness on Monday, January 14th 2013 at 13:15 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Uroplasty To Issue Third Quarter Of Fiscal 2013 Financial Results On January 24,... -- MINNEAPOLIS, Jan. 14, 2013 /PRNewswire/ --
MINNEAPOLIS, Jan. 14, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]) announced today that it will release financial results for the third quarter of fiscal 2013 ended December 31, 2012 at the market close on Thursday, January 24, 2013. The Company will host a conference call to discuss these results on Thursday, January 24, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen , President and Chief Executive Officer, and Medi Jiwani , Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-9205. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4589816#.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 |
EVC Group Doug Sherk (Investors), 415.652.9100 Jenifer Kirtland (Investors), 415.568.9349 Chris Gale (Media), 646.201.5431 |
SOURCE Uroplasty, Inc.
RELATED LINKS
[ http://www.uroplasty.com ]
